Dormancy in breast cancer

Breast Cancer: Targets and Therapy

Volumn 4, Issue , 2012, Pages 183-191

  Banys, Malgorzata ^a,b   Hartkopf, Andreas D ^a   Krawczyk, Natalia ^a   Kaiser, Tatjana ^a   Meier Stiegen, Franziska ^a   Fehm, Tanja ^a   Neubauer, Hans ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Marienkrankenhaus Hamburg ^*  (Germany)

Author keywords

Circulating tumor cell; Disseminated tumor cell; Targeted therapy; Tumor dormancy

Indexed keywords

ALDEHYDE DEHYDROGENASE; BETA1 INTEGRIN; BEVACIZUMAB; CD24 ANTIGEN; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; HERMES ANTIGEN; LAPATINIB; LONAFARNIB; OSTEOPROTEGERIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; B CELL LEUKEMIA; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CELL CYCLE ARREST; CELL PROLIFERATION; CIRCULATING TUMOR CELL; CLINICAL TRIAL (TOPIC); DORMANCY; HUMAN; IMMUNE SYSTEM; LYMPHOMA; METASTASIS; MICROMETASTASIS; MITOSIS INHIBITION; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE SRC; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84871127087     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S26431     Document Type: Review

References (84)

1. Ashworth TR. A case of cancer in which cells similar to those in tumors were seen in the blood after death. Aust Med J. 1869;(14):146-149.
2. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353(8): 793-802.
3. Becker S, Solomayer E, Becker-Pergola G, Wallwiener D, Fehm T. Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res Treat. 2007;106(2):239-243. Epub January 27, 2007.
4. Janni W, Rack B, Schindlbeck C, et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer. 2005;103(5):884-891.
5. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781-791.
6. Rack BK, Schindlbeck C, Andergassen U, et al. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. ASCO Annual Meeting 2010 [abstract]. J Clin Oncol. 2010;28:Suppl 15s:1003.
7. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 1974;34(5):997-1004.
8. Butler TP, Gullino PM. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 1975;35(3):512-516.
9. Mehes G, Witt A, Kubista E, Ambros PF. Circulating breast cancer cells are frequently apoptotic. Am J Pathol. 2001;159(1):17-20.
10. Larson CJ, Moreno JG, Pienta KJ, et al. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A. 2004;62(1):46-53.
11. Fidler IJ. Metastasis: Quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-Iodo-2′-desoxyuridine. J Natl Cancer Inst. 1970;45:773-782.
12. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol. 2001;13(5):555-562.
13. Liotta LA, Saidel GM, Kleinerman J. Stochastic model of metastases formation. Biometrics. 1976;32(3):535-550.
14. Liotta LA, Saidel MG, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 1976;36(3):889-894.
15. Banys M, Krawczyk N, Becker S, et al. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res Treat. 2012;132(1):121-129. Epub May 12, 2011.
16. Krag DN, Ashikaga T, Moss TJ, et al. Breast cancer cells in the blood: a pilot study. Breast J. 1999;5(6):354-358.
17. Luzzi KJ, Macdonald IC, Schmidt EE, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998;153(3):865-873.
18. Cameron MD, Schmidt EE, Kerkvliet N, et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 2000;60(9):2541-2546.
19. Kienast Y, Von Baumgarten L, Fuhrmann M, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med. 2010;16(1):116-122.
20. Sleeman JP, Nazarenko I, Thiele W. Do all roads lead to Rome? Routes to metastasis development. Int J Cancer. 2011;128(11):2511-2526.
21. Paget S. Distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571.
22. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9(4):285-293.
23. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820-827.
24. Erler JT, Weaver VM. Three-dimensional context regulation of metastasis. Clin Exp Metastasis. 2009;26(1):35-49.
25. Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev. 2006;25(4):521-529.
26. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat. 1996;41(2):177-185.
27. Pocock SJ, Gore SM, Kerr GR. Long term survival analysis: the curability of breast cancer. Stat Med. 1982;1(2):93-104.
28. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999;91(1):80-85.
29. Willis RA. The Spread of Tumors in the Human Body. London: J&A Churchill; 1934.
30. Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004;10(24): 8152-8162.
31. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1(2):149-153.
32. Morgan TM, Lange PH, Porter MP, et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res. 2009;15(2):677-683.
33. Goodison S, Kawai K, Hihara J, et al. Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res. 2003;9(10 Pt 1):3808-3814.
34. Wikman H, Vessella R, Pantel K. Cancer micrometastasis and tumour dormancy. APMIS. 2008;116(7-8):754-770.
35. Becker S, Becker-Pergola G, Wallwiener D, Solomayer EF, Fehm T. Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy. Breast Cancer Res Treat. 2006;97(1):91-96.
36. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994;124(4):619-626.
37. Fehm T, Mueller V, Marches R, et al. Tumor cell dormancy: implications for the biology and treatment of breast cancer. APMIS. 2008;116(7-8):742-753.
38. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7(11):834-846.
39. Hussein O, Komarova SV. Breast cancer at bone metastatic sites: recent discoveries and treatment targets. J Cell Commun Signal. 2001; 5(2):85-99.
40. Townson JL, Chambers AF. Dormancy of solitary metastatic cells. Cell Cycle. 2006;5(16):1744-1750.
41. White DE, Rayment JH, Muller WJ. Addressing the role of cell adhesion in tumor cell dormancy. Cell Cycle. 2006;5(16):1756-1759.
42. Ranganathan AC, Adam AP, Aguirre-Ghiso JA. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle. 2006;5(16):1799-1807.
43. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol. 1999;147(1):89-104.
44. Naumov GN, Macdonald IC, Weinmeister PM, et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 2002;62(7):2162-2168.
45. Fisher JL, Thomas-Mudge RJ, Elliott J, et al. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 2006;66(7):3620-3628.
46. Holen I, Cross SS, Neville-Webbe HL, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo-a role in tumour cell survival? Breast Cancer Res Treat. 2005;92(3):207-215.
47. Neville-Webbe HL, Cross NA, Eaton CL, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat. 2004;86(3):269-279.
48. Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 2009; 16(1):67-78.
49. Indraccolo S, Stievano L, Minuzzo S, et al. Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proc Natl Acad Sci U S A. 2006;103(11):4216-4221.
50. Naumov GN, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst. 2006;98(5):316-325.
51. Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet. 2002;360(9334):683-689.
52. Barkan D, Kleinman H, Simmons JL, et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 2008;68(15):6241-6250.
53. Uhr JW, Pantel K. Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A. 2011;108(30):12396-12400.
54. Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12(19):5615-5621.
55. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res. 2010;12(6):214.
56. Fournier PG, Stresing V, Ebetino FH, Clezardin P. How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia. 2010;12(7): 571-578.
57. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol. 2008;19(12):2007-2011.
58. Clezardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 2005;65(12):4971-4974.
59. Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol. Epub March 1, 2012.
60. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252-1260.
61. Mackey JR, Kerbel RS, Gelmon KA, et al. Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials. Cancer Treat Rev. 2012;38(6):673-688.
62. Solomayer EF, Becker S, Pergola-Becker G, et al. Comparison of HER2status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat. 2006;98(2):179-184.
63. Krawczyk N, Banys M, Neubauer H, et al. HER2status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2status on primary tumor. Anticancer Res. 2009;29(10):4019-4024.
64. Fehm T, Hoffmann O, Aktas B, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009;11(4):R59.
65. Fehm T, Krawczyk N, Solomayer EF, et al. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res. 2008;10(5):R76.
66. Meng S, Tripathy D, Shete S, et al. HER-2gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. 2004;101(25):9393-9398.
67. Jückstock J, Rack B, Schindlbeck C, et al. Treatment with trastuzumab in recurrence free patients with early breast cancer and persistent disseminated tumor cells (DTC) in bone marrow. Proceedings of the San Antonio Breast Cancer Symposium December 10-14, 2008; San Antonio (TX), USA.
68. Aktas B, Muller V, Tewes M, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol. 2011;122(2):356-360. Epub May 24, 2011.
69. Rack B, Juckstock J, Gunthner-Biller M, et al. Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Arch Gynecol Obstet. 2012;285(2):485-492. Epub June 30, 2011.
70. Bozionellou V, Mavroudis D, Perraki M, et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res. 2004;10(24):8185-8194.
71. Curigliano G, Spitaleri G, Pietri E, et al. Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol. 2006;17(5):750-762.
72. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst. 2012;104(8):599-613.
73. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-732.
74. Woelfle U, Cloos J, Sauter G, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res. 2003;63(18):5679-5684.
75. Weaver VM, Petersen OW, Wang F, et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol. 1997;137(1):231-245.
76. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 2003;63(7):1684-1695.
77. Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 2006;66(3): 1702-1711.
78. Matsuzawa A, Takeda Y, Narita M, Ozawa H. Survival of leukemic cells in a dormant state following cyclophosphamide-induced cure of strongly immunogenic mouse leukemia (DL811). Int J Cancer. 1991; 49(2):303-309.
79. Rabinovsky R, Uhr JW, Vitetta ES, Yefenof E. Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate. Adv Cancer Res. 2007;97:189-202.
80. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456(7222):593-598.
81. Nash KT, Phadke PA, Navenot JM, et al. Requirement of KISS1secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst. 2007;99(4):309-321.
82. Horak CE, Lee JH, Marshall JC, Shreeve SM, Steeg PS. The role of metastasis suppressor genes in metastatic dormancy. APMIS. 2008;116(7-8):586-601.
83. Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer. 2010;46(7):1181-1188.
84. Eyles J, Puaux AL, Wang X, et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest. 2010;120(6):2030-2039.